Feb 14 2012

Hikma Pharmaceuticals PLC - Voting Rights and Capital

LONDON, 14 February 2012: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 31 January 2012 its capital consists of 195,862,507 ordinary shares with voting rights. There are no shares held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.


About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma 's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma 's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2010, the Group achieved revenues of $731 million (2009 $637 million) and profit attributable to shareholders was $99 million (2009 $78 million).

Hikma Pharmaceuticals PLC
Henry Knowles
Company Secretary
+44 20 7399 2760

NASDAQ Dubai is not responsible for the content of issuer disclosures.

© Press Release 2012

© Copyright Zawya. All Rights Reserved.

Show Comments (1)

Send This Article To Your Friends

All fields are required.

Use commas for multiple email addresses

We'll use your email address to send the article on your behalf and it will not be collected or used for any other purposes.